Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
January 16 2024 - 7:30AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that Bob Smith, former Senior Vice
President, Global Gene Therapy Business at Pfizer, has joined the
Company’s Business Advisory Board (BAB). The BAB was established in
June 2023 to assist in driving public/private partnerships with
governments around the world; pursuing business collaborations,
partnerships, and licensing opportunities; creating awareness of
the Company’s differentiated capabilities; and promoting access to
the Company’s therapies around the world.
“Bob has the experience Ocugen needs to pursue business
development activities with companies that have the size and scale
to bring our gene therapies through to commercialization,” said Dr.
Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen. “He is a
consummate healthcare professional who truly understands the need
to drive the pipeline so that we can ultimately get our
first-in-class gene therapies to patients with blindness
diseases.”
For nearly eight years, Mr. Smith led Pfizer’s global gene
therapy business, including the strategic and operational
development and implementation of Pfizer’s end-to-end,
enterprise-wide efforts to be an industry leader in gene therapy.
He is an accomplished biopharmaceutical executive with over
thirty-five years’ experience in a variety of alliance management,
business development, commercial, corporate strategy, mergers
and acquisitions, and research and development executive leadership
roles.
“I am impressed with the science behind Ocugen’s modifier gene
therapy programs and look forward to introducing this novel
approach to potential business partners,” said Mr. Smith. “Having
previously worked with members of the Ocugen leadership team at
Wyeth and Pfizer, I welcome the opportunity to join the BAB and
support their short- and long-term goals for the company.”
Mr. Smith joins Connie Collingsworth, Senator Pat Toomey,
Ambassador Joseph W. Westphal, Ph.D., and Dennis Carey, Ph.D. on
the BAB. These advisors will work alongside the Executive
Leadership Team to strengthen Ocugen’s network across a variety of
stakeholders.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patient’s lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks, and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany
HamiltonHead of Corporate
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024